Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Human ACE2 transgenic pigs are susceptible to SARS-CoV-2 and develop COVID-19-like disease.
Nat Commun
January 2025
Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK.
Animal models that accurately reflect COVID-19 are vital for understanding mechanisms of disease and advancing development of improved vaccines and therapeutics. Pigs are increasingly recognized as valuable models for human disease due to their genetic, anatomical, physiological, and immunological similarities to humans, and they present a more ethically viable alternative to non-human primates. However, pigs are not susceptible to SARS-CoV-2 infection which limits their utility as a model.
View Article and Find Full Text PDFSkin inflammation and lipid disorder induced by topical application of Mal f 1.
Int Immunopharmacol
January 2025
The Second Affiliated Hospital, Guangdong Provincial Key Laboratory of Allergy & Immunology, The State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China. Electronic address:
Objected: Mal f 1, the first allergen cloned from Malassezia furfur, has been found to have positive IgE reactivity in sera from patients with skin inflammation. In vitro, it has also been shown to induce maturation of dendritic cells and release inflammatory factors. However, its role in skin lipid homeostasis remains largely unexplored.
View Article and Find Full Text PDFReduced expression of programmed cell death protein 1 on peripheral regulatory B cells in pre-eclampsia - Signs of impaired immune suppression.
J Reprod Immunol
January 2025
Department of Clinical Biochemistry, Centre for Immune Regulation and Reproductive Immunology (CIRRI), Zealand University Hospital, Sygehusvej 10, Roskilde DK-4000, Denmark; Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, Copenhagen DK-2200, Denmark; The ReproHealth Research Consortium, Zealand University Hospital, Sygehusvej 10, Roskilde DK-4000, Denmark. Electronic address:
Immunological changes are believed to be a part of pre-eclampsia etiology. This study investigated the distribution of the specific peripheral B lymphocyte phenotypes in pre-eclampsia cases compared to uncomplicated pregnancies. The study cohort included 29 women with pre-eclampsia and 14 women with uncomplicated pregnancies.
View Article and Find Full Text PDFRole of procalcitonin, C reactive protein and ferritin in cytokine release syndrome after CAR T-cell therapy in children and young adults.
Biomarkers
January 2025
Pediatric Intensive Care Unit, Hospital Sant Joan de Déu-University of Barcelona, Barcelona, Spain.
PurposeChimeric antigen receptor (CAR) T-cell CD19 therapy has changed the treatment paradigm for patients with relapsed/refractory B-cell acute lymphoblastic leukemia. It is frequently associated with potentially severe toxicities: cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and admission to PICU is often required. Some biomarkers seem to correlate with CRS severity.
View Article and Find Full Text PDFCurrent perspectives and the future of disease-modifying therapies in type 1 diabetes.
World J Diabetes
January 2025
Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, United Kingdom.
Use of immunomodulating agents to prevent the progression of autoimmune β-cell damage leading to type 1 diabetes mellitus (T1DM) is an interesting area for research. These include non-specific anti-inflammatory agents, immunologic vaccination and anti-inflammatory agents targeting specific immune cells or cytokines. Teplizumab is an anti-CD3-molecule that binds to and leads to the disappearance of the CD3/TCR complex and rendering the T cell anergic to its target antigen.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!